Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KT Wave Moves Up 28 Places in Amazon's Top 100 Since Monday
#80 0n 10/17 per post #300852
#52 Today per Amazon
"#52 in Muscle Stimulators & Accessories"
Market Makers’ Methods of Stock Manipulation
B y A.J. Cataldo , P H .D., CMA, CPA, and Larry N. Killough , P H .D., CPA
A market maker, who handles small-sized and microcap stocks; an exchange floor specialist, who is involved with mid-sized or large-capitalized stocks; or a broker-dealer, who handles all stocks, performs two separate and, apparently, incompatible functions.
First, all maintain an inventory of the stocks their firms have underwritten, continue to trade, or make a market in. They buy and sell these inventories for profit. In theory, they will buy low, which reduces the decline in price per share (PPS), and sell high, which reduces the rise in PPS. Therefore, these profit-making behaviors are presumed to provide a stabilizing effect on changes in the PPS of the stocks they make a market in.
Second, they post the bid and ask prices at which others are willing to buy or sell and match incoming buy and sell orders. In return for performing these functions, market makers or specialists generate revenue for their firm through various order-flow or transaction-fee schemes.
But like the conflicts apparent in the dual role of an analyst-broker or auditor-consultant, the broker-dealer is faced with an opportunity to sell his or her firm’s inventory before others in a declining market or buy for his or her firm’s inventory before others in a rising market. This practice is one form of market maker manipulation. It is illegal, difficult to detect, but alleged in many instances—both correctly and, often, incorrectly—on Internet stock-chat message boards. One relatively highly publicized example of MMM is referred to as front running.
In front running, specialist market makers use their knowledge of private, incoming order-flow information revealed by limit orders to generate monopolistic trading profits. Though front running per se may not be particularly damaging to your firm, it illustrates the abuse of the conflicting roles of the broker-dealer as both a facilitator of an orderly market (matching incoming orders from other investors to buy and sell) and as someone with the desire to generate profits from the
inventories traded for their firm’s account.
Another type of market manipulation is the naked short sale. Firms with a declining PPS are targeted for naked short selling. This practice is very damaging to
the publicly traded firm and may be popular among the off shore brokerage firms where U.S. securities laws are less easily enforced or do not apply. It is similar to the counterfeiting of currencies. In a naked short sale of stock, short positions are not declared or disclosed, shares are not borrowed to cover the short sale, and the stock is never delivered to the purchaser. The result is dilutive in that it results in an artificial, unauthorized, and illegal increase in the number of shares issued and outstanding and in a manipulated decline in the PPS of the firm’s stock. The broker-dealer merely floods the market with cheap, nonexistent shares of your firm’s stock. The seller of these nonexistent shares keeps the proceeds.
Read full article here, https://www.imanet.org/-/media/4c6c7650a0024853a1c61963d7865649.a
ActiPatch, Best Value in the PSWT/PEMF Universe
ActiPatch - $29 - $39 - FDA OTC Cleared for Musculoskeletal Pain
Assisi Loop (Sofpulse) 2.0 Manual Size: 10 cm - $329.00 - Prescription needed
Oska Pulse - $ 429.00 - Not FDA Cleared for any medical conditions
Truestim Genesys Neck/Universal Wrap PEMF - $4,999.00 - Prescription needed
MiraMate Big Magic - PEMF Mat For Chronic Pain - $670.00
HAELO pulsed electromagnetic field PEMF therapy - $3295.00
LMAO, First Result on Google "DonJoy Performance" Search
"DonJoy Performance | #1 Sports Medicine Brand Worldwide ...https://www.donjoyperformance.com
DonJoy Performance features an extensive line of innovative sports bracing products, Trizone, Bionic, Webtech, Anaform, POD, and Defender designed to keep"
https://www.donjoyperformance.com/
But, but, but it does not fit my agenda so it must be 'Fake News'.
...
Sounds Like Worthless Anecdotal BS
anecdotal - not necessarily true or reliable, because based on personal accounts rather than facts or research:
DonJoy Best Sellers, 8 Products Listed, EME Knee First Row, Position #4
https://www.donjoyperformance.com/?medium=tsa&gclid=5883e9d8c0ac1f7be44a8a90d36e6764&gclsrc=3p.ds&msclkid=5883e9d8c0ac1f7be44a8a90d36e6764&utm_source=bing&utm_medium=cpc&utm_campaign=S_B_DonjoyPerformance_PE&utm_term=donjoy%20performance&utm_content=Brand
Modern Development Medical Working RecoveryRx in Qatar
http://www.mdmedical.co/recoveryrx.html
http://www.mdmedical.co/actipatch.html
Doha Family
October 3 at 5:16 AM
·
Doha Family is giving away Recovery RX medical devices to the first 200 participants, completely free of charge!
Recovery RX is a class II, FDA-cleared, pulsed shortwave therapy device which utilizes non-thermal, radio-frequency electromagnetic energy to treat pain and edema.
To enter the giveaway, all you have to do is:
1. Subscribe to our newsletter: https://bit.ly/4k8GNnA
2. Like this post
The first 200 people who enter will receive the Recovery RX medical device and will be contacted with further details regarding collection.
Note: all participants must be residents of Qatar, with a Qatar ID, and only one medical device per person is allowed.
Let the giveaway begin!
https://www.facebook.com/dohafamilymagazine/
Sorry ActiPatch did not relieve your pain, But you are clearly in the Minority
US Amazon Ratings:
Knee - 646 Reviews - 76% 4 & 5 Star Rating
Muscle & Joint - 376 Reviews - 71% 4 & 5 Star Ratings
KT Wave - 775 Reviews - 71% 4 & 5 Star Ratings
UK Amazon:
Back - 881 Reviews - 81% 4 & 5 Star Ratings
"We have had amazing results, especially with post-operative pain and patient satisfaction with recovery. Often patients feel no pain post-op when using RecoveryRx. I have had patients call me days after the surgery asking when the intra-operative anesthesia will wear off. Or they call to make sure I actually did the surgery."
Portable.
Nonthermal.
Lightweight.
No kidney, liver, or bodily harm
No contraindications to medications.
Reduces post-operative edema
Promotes healing
Safe.
standalone therapy or adjunct therapy
https://bestfootdoctorny.com/recoveryrx-for-musculoskeletal-pain/
Big News on International Front
*We have signed a deal for 25 countries throughout SEA, APAC, Africa, MENA, CIS with Synergy Corporation
*The signed agreement calls for 975,000 units of RecoveryRx to be purchased over the first 18 months
* First order will occur after we successfully register our product in seven countries
* We anticipate this happening in the 4th Quarter
* Largest contract to date for BIEL
* Healthy margins and high volume
* Customer sees value and efficacy at this price point
1. Synergy PR won't happen in Q4. Keith merely said it was "anticipated" in Q4 which, in biotech Safe Harbor BS, means "best case scenario" which of course never happens. (KN stated in Conf. Call that registration would be complete in 2-3 weeks so registration will not hold up initial order, IMO by 11/15)
2. Initial order will be for about $300,000. That's a lot of money for a new product. How many units is that? What does BIEL get per unit? Who knows.( nonsense, that would be less than 30k units, IMO, it will be for 100k units or larger)
3. the second order might never come. Synergy has to discover whether or not they can sell the thing. Nobody else has been able to so the odds are against them. (everyone is entitled to an opinion but more nonsense IMO, KN spent years in pharmaceutical sales and he would not waste time with Synergy unless they had a viable marketing plan)
LOL, RecoveryRx Saves Them Money
We are talking about an expense of $30-35 for the hospital and revenue of $13k -
25k for a TKR.
The Insurance company is paying for a TKR Package & does not care what method of pain relief JIS is using as long as it is FDA Cleared/Approved and it meets the patient's needs.
A patient with significantly reduced pain/no pain and zero side effects from that pain relief will not be calling the doctor for an office visit, new prescriptions or other related therapies.
Not comprehending the Health Insurance/Hospital relationship
Health Insurers negotiate a rate with hospitals for common procedures like Total Knee Replacement. It does not matter what specific sutures, gauze or pain meds the hospital uses as it is the Hospital's TKR Program. They get paid the negotiated rate for each TKR.
So if JIS Orthopedics decides that they get fewer complications and patient complaints using RecoveryRx it becomes part of their TKR Program.
The NHS in the UK, being a National Healthcare provider, is a different situation, tightly government controlled vs the US free market. The Local CCGs control the Local hospitals, including what pain relief products they can purchase. The CCGs said no to ActiPatch. The National NHS Drug Tariff Approval did not help BIEL as the CCGs control all money spent in their communities. The NHS has had budgets restricted for the last 10 years so the CCGs place every expense under a microscope trying to save money.
The initial Synergy order will hit in Q4. There will be an official PR announcing the signed deal and hopefully lay some of your agnst to rest.
US Health Insurers not approving Electromagnetic Therapy does not prevent Orthopedic Surgery Hospitals from using RecoveryRx.
JIS Orthopedics in Ohio uses RecoveryRx.
https://www.jointimplantsurgeons.com/
https://twitter.com/keith_nalepka/status/1564249807660646405/photo/1
Health Insurers use the "Insufficient Evidence" excuse on all sorts of Drugs/Medical Devices. They want Clinical Trials with thousands of patients which would cost millions of dollars.
"Cranial electrotherapy stimulation (CES), also known as ...https://www.bcbsri.com › files › policies › 2022/04 PDF, evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Electrical stimulation of auricular..."
" Progesterone Therapy as a Technique to Reduce Preterm...https://www.southcarolinablues.com › external-policies
The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. For individuals with a singleton pregnancy..."
"Sacral Nerve Neuromodulation/Stimulation - Accrue Healthhttps://www.accrue-health.com › web › external-policies
The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. For individuals with chronic pelvic pain ..."
"Transmyocardial Revascularization? | BlueCross BlueShield of ...https://member.myhealthtoolkitla.com › external-policies
The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. The purpose of the following information ..."
"Extracorporeal Photopheresis? | BlueCross BlueShield of ...https://member.myhealthtoolkitks.com › external-policies
The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Lung Transplant"
"Interim Positron Emission Tomography Scanning in Oncology ...https://www.bcbsnd.com › ... › Medical Policy
The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Esophageal Cancer."
"Spinal Cord and Dorsal Root Ganglion Stimulation - CAM 70125https://www.southcarolinablues.com › external-policies
The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. Treatment-Refractory Angina Pectoris"
The examples go on and on as Health Insurers feel they reduce exposure to potential costs by limiting the authorized treatments.
...
You have to access the DonJoy Performance Website
Knee product is listed on the 'Best Sellers' .
https://www.donjoyperformance.com/?medium=tsa&gclid=ee2551b9f1da109b78fe3286f060432f&gclsrc=3p.ds&msclkid=ee2551b9f1da109b78fe3286f060432f&utm_source=bing&utm_medium=cpc&utm_campaign=S_B_DonjoyPerformance_PE&utm_term=donjoy%20performance&utm_content=Brand
https://www.donjoyperformance.com/knee
https://www.donjoyperformance.com/back
LOL, Using Judges that the SEC could hire and fire and knew were illegal to get a 90 percent conviction rate is a technicality ???
"the rest of that story"
The SCOTUS ruled that the SEC used Unconstitutional Judges and reversed hundreds of the SEC's fraudulently obtained rulings, BIEL being one of them.
BIEL settled with the SEC for less than 10% of their original judgement because it was cheaper than going through a new Administrative Procedure with the SEC.
The frigging Security and Exchange Commission used unconstitutional Judges to improve their conviction numbers. Let that sink in. And they had been warned of the violation of law by numerous sources for years before the issue made its way to the SCOTUS.
Be Ware "BIEL Experts" giving investment advice after spending 7 minutes on DuckDuckgo
LOL, 2018 Regurgitated once again, it was called the Innovation Challenge
250 companies entered the FDA Innovation Challenge and only 2 were selected in the Pain category.
Pfizer, with a R&D budget of hundreds of millions of $$$$$$$$$ entered the Challenge and had the same result as BIEL who had a R&D budget of $496k.
More Total BS .....
KW needs the BOD approval for either a RS or a AS increase and it won't be a surprise, public notice is required.
There has to be a Market for converted shares or they are not sellable.
Half of ZERO is ZERO. Lenders need a successful BIEL to get repaid.
100 percent toohot, I am also of the opinion that since the 3 largest lenders are the CEO of BIEL, Wife of the Founder, and Chairman of the BIEL BOD, they will probably take their Loan pay back over time in cash from BIEL profits rather than a BIEL share conversion.
Total BS, Only 295 million Shares of BIEL's Authorized Shares are Available
<<<<<<<<<<<< HUGE PROFITS whenever she wants >>>>>>>>>>>>
An AS Increase or a RS would have to be done before she could convert her Loans. Either one would require advance public notice which would cause a sell off unless done after BIEL is producing large consistent profits.
KW and St John's are committed to bringing BIEL to profitability as demonstrated by the forgoing of $2.5 million in Loan Interest and the repeated Roll Over of millions of dollars in Loans that had reached maturity. Without these Roll Overs BIEL would have needed to do an Authorized Share increase years ago.
The only way KW $6 million, St John's $3.2 million, and Dr. Staelin $857k, get their Loans paid back is if BIEL becomes a successful company. That's a very large incentive to make BIEL solvent which will benefit both Shareholders and Lenders.
Must be another 'Fantasy Sales Track' statistic
<<<<<<<<<<<<< 99.999% of surgeons >>>>>>>>>>>>>>>
<<<<<<<<< Everything I say and write is my opinion and my opinion only >>>>>>>>>>
Forgot to mention that $1.5 million of 2023 maturing Loans are with 'Friendly Lenders' that have Rolled Over Loans in the past.
The remaining $511k is not due until 11/15/2023 and is with the EXIM Bank who BIEL has been using for loans since 2015.
RecoveryRX XTRA should qualify for a "Special 510k", 30 Day process
“The Special 510(k) Program” guidance document, issued in September 2019, describes an optional pathway for manufacturers that make certain well-defined modifications to their own legally marketed device. The guidance was developed to clarify existing policy and the types of changes that are appropriate for the program in an effort to improve the efficiency of 510(k) review, consistent with the FDA’s least burdensome principles. The program allows FDA and industry to rely on previous agency review of detailed information and manufacturers to provide the minimum required information necessary to establish substantial equivalence (SE) for a modified device. As a result, special 510(k)s are processed within 30 days of receipt by the Document Control Center instead of 90 days as for Traditional or Abbreviated 510(k)s.
Must be looking at the wrong stock, BIEL has 5 FDA Indications via 4 510Ks
K022404 - 8/8/2002, For the treatment of edema following Blepharoplasty
K152432 - 2/3/2017, Adjunctive treatment of musculoskeletal pain related to: (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee.
K190251 - 5/30/2019, Adjunctive treatment of postoperative pain
K192234 - 1/31/2020, Adjunctive treatment of musculoskeletal pain
IMO, the Antenna is the only change to the RecoveryRX XTRA
In BIEL's 8/25 Call KN said, regarding the new RecoveryRX, it had an "oblong antenna" and their feeling was that it would not need a new 510k. He also mentioned a working prototype for a Rechargeable Device that would need a new 510k.
Changing the antenna shape to an elongated rectangle focuses the power more directly on a typical surgical incision.
The RecoveryRX XTRA has the same power as the RecoveryRx and the ActiPatch, 73mw, it is just directed in a rectangular pattern rather than a circular pattern.
The 2019 FDA Clearance k193234 for Musculoskeletal Pain states that the ActiPatch comes with either a 12cm or a 6cm antenna. This shows very clearly that different antenna configurations are not a significant factor for the FDA.
https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192234.pdf
Is a new 510(k) required for a modification to the device?
The RecoveryRX XTRA has the same electronics, battery, off/on function as the Cleared RecoveryRx device. The change is in the Antenna shape, originally circular to rectangular to better fit surgical wounds.
FDA
Is a new 510(k) required for a modification to the device?
Introduction
Medical devices undergo frequent modifications to their design and materials due to many things; changes in the supply chain, continuous process improvement, or to keep pace with technological innovations that can improve how these devices work in a clinical setting. Major modifications to the device likely require premarket review by the FDA, while minor changes likely do not.
A premarket notification (510(k)) is required when a legally marketed device subject to 510(k) requirements is significantly changed or modified in design, components, method of manufacture, or intended use. Significant changes or modifications are those that could significantly affect the safety or effectiveness of the device, or major changes or modifications in the intended use of the device (21 CFR 807.81(a)(3)).
The regulatory language provides essential flexibility instead of rigidly defining the types of changes that require FDA review. Appropriate application of this flexibility enables innovation and ensures Agency oversight only when necessary. For some types of changes to a device, the Agency believes that submission of a new 510(k) is not required and that reliance on existing Quality System (QS) requirements (21 CFR 820) is the least burdensome approach to reasonably assure the safety and effectiveness of the changed device.
https://cacmap.fda.gov/medical-devices/premarket-notification-510k/new-510k-required-modification-device#:~:text=Major%20modifications%20to%20the%20device%20likely%20require%20premarket,design%2C%20components%2C%20method%20of%20manufacture%2C%20or%20intended%20use.
You Can't Make This Stuff Up, ENDV Off the Rails
Endonovo, which sold $650 of its only product Sofpulse in Q2 2022, has signed an agreement to purchase a concrete company in Texas, estimated to be a $25 million deal.
ENDV tried to sue BIEL a few years back for patent infringement, the case was dismissed by a judge.
ENDV issued a PR last month claiming their Sofpulse was better than RecoveryRx.
From a medical device company to the concrete business, Adios ENDV.
https://ir.endonovo.com/press-releases/detail/304/endonovo-therapeutics-signs-definitive-asset-purchase
The UK is educating medical professionals about ActiPatch
SMAE Institute UK
Founded in 1919, we are the longest running independent provider of training in Foot Health in the UK, with a reputation for excellence in teaching and pastoral support. We offer the only University Credit Rated Foot Health Course in the UK. Our FHP Diploma is Credit Rated by Queen Margaret University and carries 60 Higher Education Credits at Level 4. We are the only Institute who offer an FHP Diploma at this level.
October 7 2022
9.30am – 10.30am Raymond Robinson MSc, BSc, BMedSci, PgCHEP,
Course Director Podiatry, Ulster University
Pulsed radiofrequency energy (PRFE) – a little known gem in the
armoury of physical therapies for MSK management?
Radiofrequency energy treatment has been used for some decades in the
management of musculoskeletal (MSK) pain. More recently, devices have
become miniaturised, portable and available in the UK as an over-thecounter (OTC) ‘topical’ analgesic for localized MSK pain and injury (ActiPatch®
BioElectronics Corporation, MD, USA).
As an acute muscle pain treatment, the ActiPatch device has been
demonstrated to significantly reduce postoperative pain and the requirement
for narcotic pain medications in submuscular breast augmentation patients.
In two chronic musculoskeletal pain conditions, plantar fasciitis and
osteoarthritis of the knee, the device was also found to significantly reduce
pain and medication use.
This talk will review the efficacy, safety and cost effectiveness of this form of
physical therapy to assist practitioners in decision making on the use of this
treatment for their patients.
https://www.smaeinstitute.co.uk/Uploads/SMAE_2022_Summer_School_in_the_Fall_Agenda.pdf
https://www.smaeinstitute.co.uk/about-us/
Thanks for sharing toohot, So actual shareholders don't want to sell at 7
MMs, whose job title is to 'Make a Market'', who can sell shares that they don't own and have not borrowed, don't want to sell at 7.
Sounds like we may be approaching a Material Event PR.
Ruh Roh, KT Wave Moves Up to #48 on Amazon Top Sellers
#48 out of 632 products in the Muscle Stimulators & Accessories category.
Up 16 positions since Tuesday's #64.
Why didn't 'Fantasy Sales Track' warn us about this significant increase in sales???
Did you specifically ask Paul if Synergy was an OEM deal or a Distributor deal?
Because he did not answer that specific question.
I am sure you noticed that he did not use the word 'Distributor' or 'Distribution' in his reply.
He also did not use the trademark 'RecoveryRx' name instead using 'RecoveryRX'.
Paul also said " promoting the product via a traditional device company marketing and launch plan". Shouldn't he have said, 'traditional distribution company'?
The BIEL VP of Sales and BOD Member stated, "Our OEM plan is clicking as we have added 25 new countries, SEA, APAC, CIS, Africa, MENA". There is no doubt that he was referring to the Synergy Deal.
The public relations rep, Paul, did not call it a Distribution Deal, after working at BIEL for more than a decade did not use the RecoveryRx trademark, and said the promotion would be "traditional device company marketing" not 'distributor marketing'.
I am going to side with our VP of Sales on this issue as he is the one who spent months hammering out the Deal with Synergy and knows what type of contract he drafted.
BIEL currently refers to KT Tape as their US Distributor
A look at the 'ActiPatch® Worldwide Distributors' map and one sees that BIEL considers KT Tape, who is an OEM Partner, a US Distributor.
https://www.actipatch.com/distributors/
Way too much concern over Synergy being an OEM or a Distributor, they can be both just like KT Tape.
KN on Linkedin last month,
"We are small but pack a big punch, great company coverage @microcapdaily as we increase our global footprint and drive to revenue growth. Our OEM plan is clicking as we have added 25 new countries, SEA, APAC, CIS, Africa, MENA. Disruptive technology providing pain relief w/no interactions, lowering oral meds by 50+ percent"
https://www.linkedin.com/feed/update/urn:li:activity:6970397429175050241/
Typical attempt at spreading fear and doubt TP
Happens every time BIEL has a positive event.
BIEL has known it was an OEM Deal for many months and they stated in a written company document on 8/25:
"First order will occur after we successfully Register our product in 7 countries"
"975,000 units of RecoveryRx to be purchased over the first 18 months"
"Largest contract to date for BIEL"
"Healthy margins and high volume"
Nothing has changed. No "wrench" has been thrown.
Hmmm, "No Credibility", interesting accusation given the fact that 'Fantasy Sales Track' is presented as factual information on a weekly basis.
BIEL stated this information in a public Conference Call:
* Signed Deal with Synergy Corporation
* 25 countries
* 975,000 RecoveryRx Units in first 18 months
* First Order Trigger is Registration in Seven Countries
* Largest Contract to Date for BIEL
* Healthy Margins and High Volume
Please fill free to contact the SEC if you have any proof that any of these statements are false.
"We have a signed deal for 25 countries Throughout SEA, APAC, Africa, MENA, CIS, with Synergy Corporation."
BIEL was pretty clear in their Conference Call.
See printed document from Call here,
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169805137
Missed this, KN said the 25 Country Deal (Synergy) is OEM in a Linkedin post
IMO, a lot more skin in the game for an OEM Contract vs a Distributor.
Keith Nalepka
• Following
Vice President of Sales and Marketing at BioElectronics Corporation, Board Member BioElectronics
1mo • 1 month ago
We are small but pack a big punch, great company coverage @microcapdaily as we increase our global footprint and drive to revenue growth. Our OEM plan is clicking as we have added 25 new countries, SEA, APAC, CIS, Africa, MENA. Disruptive technology providing pain relief w/no interactions, lowering oral meds by 50+ percent
https://www.linkedin.com/feed/update/urn:li:activity:6970397429175050241/
Great News JGD, RecoveryRx XTRA is moving through the FDA Medical Device protocol for gaining Clearance
And we have a confirmed name for BIEL's newest product, 'RecoveryRx XTRA' !!!
Go BIEL !!!
Go RecoveryRx XTRA !!!